Inhibikase Therapeutics (IKT)
(Delayed Data from NSDQ)
$1.17 USD
+0.02 (1.74%)
Updated Sep 27, 2024 04:00 PM ET
After-Market: $1.17 0.00 (0.00%) 6:58 PM ET
4-Sell of 5 4
F Value C Growth F Momentum F VGM
Income Statements
Fiscal Year end for Inhibikase Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 3 | 1 | 1 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 3 | 1 | 1 |
Selling & Adminstrative & Depr. & Amort Expenses | 20 | 18 | 18 | 4 | 7 |
Income After Depreciation & Amortization | -20 | -18 | -15 | -3 | -6 |
Non-Operating Income | 1 | 0 | 0 | 0 | 0 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -19 | -18 | -15 | -3 | -6 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -19 | -18 | -15 | -3 | -6 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -19 | -18 | -15 | -3 | -6 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -20 | -18 | -15 | -3 | -6 |
Depreciation & Amortization (Cash Flow) | 0 | 0 | 0 | 0 | 0 |
Income After Depreciation & Amortization | -20 | -18 | -15 | -3 | -6 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 5.33 | 4.20 | 3.04 | 1.37 | NA |
Diluted EPS Before Non-Recurring Items | -3.57 | -4.32 | -4.86 | -2.10 | NA |
Diluted Net EPS (GAAP) | -3.57 | -4.32 | -4.86 | -2.10 | -4.20 |
Fiscal Year end for Inhibikase Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 0.00 | 0.00 | 0.00 | 0.08 | 0.12 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 0.00 | 0.00 | 0.00 | 0.08 | 0.12 |
SG&A, R&D, and Dept/Amort Expenses | 5.05 | 4.78 | 4.40 | 4.85 | 6.32 |
Income After SG&A, R&D, and Dept/Amort Expenses | -5.05 | -4.78 | -4.40 | -4.77 | -6.20 |
Non-Operating Income | 0.09 | 0.13 | 0.64 | 0.00 | 0.42 |
Interest Expense | 0.00 | 0.00 | 0.41 | -0.17 | 0.00 |
Pretax Income | -4.96 | -4.65 | -4.18 | -4.60 | -5.78 |
Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -4.96 | -4.65 | -4.18 | -4.60 | -5.78 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -4.96 | -4.65 | -4.18 | -4.60 | -5.78 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 7.54 | 6.34 | 6.60 | 5.34 | 5.23 |
Diluted EPS Before Non-Recurring Items | -0.66 | -0.73 | -0.63 | -0.86 | -1.11 |
Diluted Net EPS (GAAP) | -0.66 | -0.73 | -0.64 | -0.86 | -1.11 |